论文部分内容阅读
目的:观察FOLFOX4和XELOX新辅助化疗方案治疗局部进展期胃癌的疗效和毒副作用。方法:68例初治确诊为局部进展期胃癌的患者,随机分为两组,每组各34例,分别采用XELOX和FOLFOX4化疗方案行术前两个疗程的化疗治疗。结果:XELOX组总有效率为47.06%,FOLFOX4组总有效率为41.08%,两组间无显著性差异。不良反应方面,FOLFOX4组恶心、呕吐,白细胞减少和口腔黏膜炎发生率较高,而XELOX组手足综合症发生率较高。结论:XELOX方案作为胃癌新辅助化疗方案,疗效与FOLFOX4方案相似,但XELOX方案副作用较轻且均可控制,化疗时间短,对机体损伤小,易于接受,值得在临床工作中进一步研究和推广。
Objective: To observe the efficacy and side effects of neoadjuvant chemotherapy with FOLFOX4 and XELOX in the treatment of locally advanced gastric cancer. Methods: Sixty-eight patients with newly diagnosed locally advanced gastric cancer were randomly divided into two groups with 34 cases in each group. The patients were treated with XELOX and FOLFOX4 chemotherapy respectively for two courses of chemotherapy. Results: The total effective rate was 47.06% in XELOX group and 41.08% in FOLFOX4 group, with no significant difference between the two groups. Adverse reactions, FOLFOX4 nausea, vomiting, leukopenia and oral mucositis incidence was higher, and XELOX group of hand-foot syndrome higher incidence. Conclusion: As a neoadjuvant chemotherapy regimen for gastric cancer, XELOX regimen has similar curative effect to FOLFOX4 regimen. However, the side effects of XELOX regimen are light and can be controlled. The chemotherapy time is short and the damage to the body is small and easy to accept. It is worth further study and promotion in clinical work.